Capricor Therapeutics Inc. (CAPR), which recently received a setback from the FDA regarding its cell therapy for Duchenne muscular dystrophy, remains confident in its potential and is looking to the upcoming HOPE-3 trial results to support its regulatory progress.
The investigational treatment in focus, Deramiocel (CAP-1002), is made from allogeneic cardiosphere-derived cells (CDCs), a rare type of heart cell that has shown strong anti-inflammatory and anti-fibrotic effects in both preclinical and clinical studies. These effects help protect heart and muscle function in conditions like Duchenne muscular dystrophy.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.